Latest Period
Q1 2026
Security Snapshot
EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) Institutional Ownership
CUSIP: 269796108
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
2
Shares (Excl. Options)
12,350
Price
$0.34
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- EGRX
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 12,350
- Total 13F value
- $4,212
- Share change
- 0
- Number of holders
- 2
- Shares outstanding
- 13,080,549
- SEC-reported price per share
- $0.67
Latest holder snapshot
3 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- EGRX - EAGLE PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 269796108.
- 2 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 2 to 2 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $4,212 to $8,275.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 2 institutions filings for Q1 2026.
Security key
269796108
Latest holder period
Q1 2026
13F holders
2
13D/G owners
4
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 269796108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
EGRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 38% | 0% | $14,341,106 | 4,945,209 | 0% | Nantahala Capital Management, LLC | 30 Jun 2025 | |
| Union Square Park Capital Management, LLC | 11% | $2,911,927 | 1,485,677 | Union Square Park Partners, LP | 31 Dec 2024 | |||
| Nantahala Capital Partners Limited Partnership | 6.2% | $1,588,835 | 810,630 | NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 16 Feb 2025 | |||
| J. Goldman & Co LP | 5.1% | $1,934,613 | 667,108 | J. Goldman & Co LP | 30 Jun 2025 |
As of 31 Mar 2026, 2 institutional investors reported holding 12,350 shares of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX). This represents 0.09% of the company’s total 13,080,549 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q1 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 12,350 | $8,275 | $0.67 | 2 | |
| 2026 Q1 | 12,350 | $4,212 | $0.34 | 2 | |
| 2025 Q4 | 12,350 | $8,645 | $0.70 | 2 | |
| 2025 Q3 | 12,350 | $33,345 | $2.70 | 2 | |
| 2025 Q2 | 12,350 | $35,815 | $2.90 | 2 | |
| 2025 Q1 | 12,350 | $12,103 | -$32,539 | $0.98 | 2 |
| 2024 Q4 | 78,976 | $38,714 | -$31,377,862 | $0.50 | 9 |
| 2024 Q3 | 8,556,159 | $31,916,789 | -$6,512,467 | $3.73 | 64 |
| 2024 Q2 | 9,907,127 | $55,472,621 | -$2,769,706 | $5.60 | 74 |
| 2024 Q1 | 10,455,755 | $54,790,054 | +$2,570,043 | $5.24 | 91 |
| 2023 Q4 | 10,021,708 | $52,411,739 | -$16,507,736 | $5.23 | 102 |
| 2023 Q3 | 10,333,726 | $162,886,680 | -$8,341,006 | $15.77 | 106 |
| 2023 Q2 | 10,767,596 | $209,255,589 | -$25,534,292 | $19.44 | 121 |
| 2023 Q1 | 11,782,526 | $334,237,088 | +$6,369,431 | $28.37 | 153 |
| 2022 Q4 | 11,558,157 | $337,854,292 | +$2,935,043 | $29.23 | 152 |
| 2022 Q3 | 11,476,393 | $303,246,716 | -$16,367,643 | $26.42 | 141 |
| 2022 Q2 | 11,608,596 | $515,754,776 | +$21,309,292 | $44.43 | 157 |
| 2022 Q1 | 11,218,058 | $555,064,605 | -$3,379,103 | $49.49 | 157 |
| 2021 Q4 | 11,262,141 | $573,200,097 | -$47,669,318 | $50.92 | 161 |
| 2021 Q3 | 11,827,478 | $659,535,787 | -$11,267,302 | $55.78 | 150 |
| 2021 Q2 | 12,049,241 | $515,950,498 | -$4,645,556 | $42.80 | 139 |
| 2021 Q1 | 12,187,000 | $508,354,422 | -$2,904,655 | $41.74 | 149 |
| 2020 Q4 | 12,322,577 | $573,859,683 | -$7,942,717 | $46.57 | 159 |
| 2020 Q3 | 12,528,383 | $532,186,860 | -$18,590,729 | $42.48 | 166 |
| 2020 Q2 | 12,979,990 | $622,793,103 | -$13,107,477 | $47.98 | 159 |